ReviewCurrent pain and headache reports2025
Periosteal Osteosarcoma: Emerging Clinical Concepts, Evolving Treatment Options: A Narrative Review.
Review in Current pain and headache reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewPeriosteal osteosarcomas are rare bone tumors that comprise less than 2% of all bone malignancies. The tumor was previously thought to affect the diaphysis of long bones solely, but Recent case reports have demonstrated its existence in the clavicle, mandible, and scapula. RECENT
findingsSeveral factors, including stage, grade, and medullary invasion primarily drive survival and recurrence of periosteal osteosarcomas. Related to its rarity, little data currently exists regarding optimum treatment strategies, including limb amputation, surgical resection, and chemotherapy in the neoadjuvant/adjuvant setting. In this regard, bone pain is the most common manifestation. Pain treatment can include medications such as oral or transdermal opioids. Adjuvant drugs can reduce inflammation and neuropathic pain, including corticosteroids, gabapentinoid agents such as gabapentin or pregabalin, lidocaine patches, tricyclic antidepressants such as amitriptyline, nortriptyline, and desipramine, or selective serotonin-norepinephrine reuptake inhibitors such as duloxetine and venlafaxine. More advanced pain treatment interventions can be provided by interventional pain medicine physicians, such as radiofrequency ablation, peripheral nerve stimulation, spinal cord stimulation, or intrathecal drug delivery systems, when conventional opioids and adjuvants do not adequately provide relief. Molecular workups of case reports have shown common mutations, such as the p53 gene, which may provide utility for future molecular targets. The present investigation aims to synthesize currently available data on periosteal osteosarcomas, including common clinical, histologic, and radiographic presentations. In addition, this review aims to further examine the potential for biomarkers and provide recommendations for treatment and future research direction.
Indexed as
Identifiers
41396348What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.